


FORM PTO 1390 (REV. 5-95)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY DOCKET NUMBER 2001_1298A	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. §371				U.S. PATENT OFFICE (if known, add 37 CFR § 2) NEW	
International Application No. PCT/JP00/01697		International Filing Date March 21, 2000		Priority Date Claimed March 20, 1999	
Title of Invention RHEUMATOID ARTHRITIS GENE AND METHOD FOR DIAGNOSING RHEUMATOID ARTHRITIS					
Applicant(s) For DO/EO/US Shunichi SHIOZAWA and Koichiro KOMAI					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. §371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. §371. 3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. §371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. §371(b) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. §371(c)(2)) a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US) 6. <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. §371(c)(2)). ATTACHMENT A 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. §371(c)(3)). a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19. 9. <input checked="" type="checkbox"/> An unexecuted oath or declaration of the inventor(s) (35 U.S.C. §371(c)(4)). ATTACHMENT B 10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. §371(c)(5)). Items 11. to 14. below concern other document(s) or information included: 11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. ATTACHMENT C <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input checked="" type="checkbox"/> Other items or information: DISKETTE CONTAINING SEQUENCE LISTING					

THE COMMISSIONER IS AUTHORIZED
 TO CHARGE ANY DEFICIENCY IN THE
 FEE FOR THIS PAPER TO DEPOSIT
 ACCOUNT NO. 23-0975.

U.S. APPLICATION NO. 09/036989 NEW		INTERNATIONAL APPLICATION NO. PCT/IP00/01697		ATTORNEY'S DOCKET NO. 2001 1298A	
15. <input checked="" type="checkbox"/> The following fees are submitted				CALCULATIONS	PTO USE ONLY
BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)): Neither international preliminary examination fee nor international search fee paid to USPTO and International Search Report not prepared by the EPO or JPO \$1000.00 International Search Report has been prepared by the EPO or JPO \$ 860.00 International preliminary examination fee not paid of USPTO but international search paid to USPTO \$ 710.00 International preliminary examination fee paid to USPTO but claims did not satisfy provisions of PCT Article 33(1)-(4) \$ 690.00 International preliminary examination fee paid of USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$ 100.00				\$860.00	
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$860.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
Claims	Number Filed	Number Extra	Rate		
Total Claims	-20 =		X \$18.00	\$	
Independent Claims	-3 =		X \$80.00	\$	
Multiple dependent claim(s) (if applicable)			+ \$270.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$860.00	
<input type="checkbox"/> Small Entity Status is hereby asserted. Above fees are reduced by 1/2.				\$	
SUBTOTAL =				\$860.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				+ \$	
TOTAL NATIONAL FEE =				\$860.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +				\$	
TOTAL FEES ENCLOSED =				\$860.00	
				Amount to be refunded	\$
				Amount to be charged	\$
a. <input checked="" type="checkbox"/> A check in the amount of <u>\$860.00</u> to cover the above fees is enclosed. A duplicate copy of this form is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 23-0975 in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>23-0975</u> .					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
19. CORRESPONDENCE ADDRESS <div style="text-align: center;">  000513 PATENT TRADEMARK OFFICE </div>			By: <u>Warren M. Cheek, Jr.</u> Warren M. Cheek, Jr., Registration No. 33,367 WENDEROTH, LIND & PONACK, L.L.P. 2033 "K" Street, N.W., Suite 800 Washington, D.C. 20006-1021 Phone: (202) 721-8200 Fax: (202) 721-8250 September 19, 2001		

[CHECK NO. 46533]

[2001_1298A]

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Shunichi SHIOZAWA et al. : Attn: BOX PCT
Serial No. NEW : Docket No. 2001_1298A
Filed September 19, 2001 :

RHEUMATOID ARTHRITIS GENE AND METHOD
FOR DIAGNOSING RHEUMATOID ARTHRITIS
[Corresponding to PCT/JP00/01697 Filed March 21, 2000]

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents,
Washington, DC 20231

Sir:

Prior to calculating the filing fee, please amend the above-identified application as follows:

IN THE SPECIFICATION

Page 1, immediately after the title, please insert:

This application is a 371 of PCT/JP00/01697 filed March 21, 2000.

IN THE CLAIMS

Please amend the claims as follows:

Claim 3. (Amended) A DNA fragment, which is a part of the disease gene of claim 1, and contains the base sequence of SEQ ID NO: 3.

Claim 6. (Amended) An antibody against the protein of claim 4.

Claim 7. (Amended) A method for diagnosing rheumatoid arthritis, comprising the detection of the mRNA from the disease gene of claim 1, in a biological specimen.

Please add the following new claims:

9. A DNA fragment, which is a part of the cDNA of claim 2, and contains the base sequence of SEQ ID NO: 3.

10. An antibody against the peptide of claim 5.

11. A method for diagnosing rheumatoid arthritis, comprising the detection of the mRNA from the protein of claim 4, in a biological specimen.

REMARKS

The specification has been revised to reflect the 371 status. In addition, the multiple dependencies of the claims have been removed to reduce the PTO filing fee.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached pages are captioned "Version with markings to show changes made".

Respectfully submitted,

Shunichi SHIOZAWA et al.

By Warren M. Cheek, Jr.
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/dlk
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
September 19, 2001

DESCRIPTION

RHEUMATOID ARTHRITIS GENE AND

METHOD FOR DIAGNOSING RHEUMATOID ARTHRITIS

5 This application is a 371 of PCT/JP00/01697 filed March 21, 2000.

Technical Field

The present invention relates to the disease gene of
rheumatoid arthritis present in the human X chromosome and a
method for diagnosing rheumatoid arthritis by detecting the
10 presence of the disease gene or its expression product.

Background Art

Although aspects, particularly the pathological process, of arthritis and arthritis mutilans which cause rheumatoid arthritis, have been clarified through various investigations, 15 because most autoimmune diseases associated with rheumatoid arthritis developed or worsen into the disease only when various causative factors coincide, the interaction itself of multiple factors must be clarified to understand the disease and to develop 20 appropriate methods of treatment.

The number of patients with rheumatoid arthritis in the world is 1% or less (N. Engl. J. Med. 322: 1277-1289, 1990), but among sibilings of patients, over 8% develop the disease (Cell. 85: 311-318, 1996), which leads to the notion that some genetic factor may be involved. However, molecular genetic

CLAIMS

1. A disease gene for rheumatoid arthritis, which is a mutant of protooncogene Dbl transcribing an mRNA that encodes the cDNA of which the sequence from the 2679th to 2952nd bases is shown in SEQ ID NO: 1, which disease gene transcribes an mRNA encoding the cDNA of which the region from the 20th to 274th bases in SEQ ID NO: 1 is substituted with the sequence of SEQ ID NO: 2.
2. The cDNA of the disease gene of claim 1.
3. A DNA fragment, which is a part of the disease gene of claim 1 ~~or the cDNA of claim 2~~, and contains the base sequence of SEQ ID NO: 3.
4. A protein which is an expression product of the disease gene of claim 1, wherein the amino acid sequence of the C-terminal is that shown in SEQ ID NO: 2.
5. A peptide, which is a part of the protein of claim 4, and contains partial sequence of the amino acid sequence shown in SEQ ID NO: 2.
6. An antibody against the protein of claim 4 ~~or the peptide of claim 5~~.
7. A method for diagnosing rheumatoid arthritis, comprising the detection of the mRNA from the disease gene of claim 1 ~~or the protein of claim 4~~, in a biological specimen.
8. A method for functionally complementing Dbl deficiency.

DESCRIPTION

RHEUMATOID ARTHRITIS GENE AND
METHOD FOR DIAGNOSING RHEUMATOID ARTHRITIS

5

Technical Field

The present invention relates to the disease gene of
rheumatoid arthritis present in the human X chromosome and a
method for diagnosing rheumatoid arthritis by detecting the
presence of the disease gene or its expression product.

10

Background Art

Although aspects, particularly the pathological process,
of arthritis and arthritis mutilans which cause rheumatoid
arthritis, have been clarified through various investigations,
because most autoimmune diseases associated with rheumatoid
arthritis developed or worsen into the disease only when various
causative factors coincide, the interaction itself of multiple
factors must be clarified to understand the disease and to develop
appropriate methods of treatment.

15

20

The number of patients with rheumatoid arthritis in the
world is 1% or less (N. Engl. J. Med. 322: 1277-1289, 1990),
but among sibilings of patients, over 8% develop the disease
(Cell. 85: 311-318, 1996), which leads to the notion that some
genetic factor may be involved. However, molecular genetic

25

procedures and genetic engineering processes used conventionally to discover the genetic factor of diseases may not be effective for autoimmune diseases. Such problem is caused by the fact that autoimmune diseases do not develop through mechanisms as simple as those of cancer, wherein abnormal growth of one mutated gene occurs. Further, although classical genetic procedures which search for genetic basis of a disease revealed that autoimmune diseases are caused by multiple genetic factors, it has not been successful in discovering its entrails or its body. Thus, almost nothing about the entity, or even the locus, of genes associated with rheumatoid arthritis has been known.

By performing linkage analysis using microsatellite markers on rheumatoid arthritis patients and their relatives, the present inventors identified three loci of rheumatoid arthritis genes (International Immunology 10(12): 1891-1895, 1998; Journal of Clinical Rheumatology 4(3): 156-158, 1998) and filed a patent application for the following disease genes (PCT/JP98/01665).

(1) A disease gene of rheumatoid arthritis located within +1 centi Morgan vicinity of a DNA sequence on human chromosome 1 to which microsatellite marker(s) D1S214 and/or D1S253 hybridize(s).

(2) A disease gene of rheumatoid arthritis located within +1 centi Morgan vicinity of a DNA sequence on human chromosome 8 to which microsatellite marker D8S556 hybridizes.

(3) A disease gene of rheumatoid arthritis located within ± 1 centi Morgan vicinity of a DNA sequence on human chromosome X to which microsatellite marker(s) DXS1001, DXS1047, DXS1205, DXS1227 and/or DXS1232 hybridize(s).

5 The present inventors identified, as a result of further studies on each of the rheumatoid arthritis genes specified in the above-described previous application, the specific gene regarding the disease gene (3) described above and determined its molecular structure.

10 Disclosure of Invention

In order to solve the above-described problems, the present invention provides a disease gene for rheumatoid arthritis, which is a mutant of protooncogene Dbl transcribing an mRNA that encodes the cDNA of which the sequence from the 2679th to 2952nd bases is shown in SEQ ID NO: 1, which disease gene transcribes an mRNA encoding the cDNA of which the region from the 20th to 274th bases in SEQ ID NO: 1 is substituted with the sequence of SEQ ID NO: 2.

15 20 The present invention also provides a cDNA of the above disease gene, a DNA fragment, which is a part of such cDNA, a protein expressed by the above disease gene, a peptide which is a part of such protein, and an antibody against such protein.

Further, the present invention provides a method for
25 diagnosing rheumatoid arthritis comprising the detection of the

mRNA from the above disease gene or the above protein in a biological specimen.

The present invention further provides a method for the functionally complementing Dbl deficiency.

5

Best Modes for Carrying Out the Invention

Hereinafter, embodiments of the present invention having the above-described characteristics will be described.

The rheumatoid arthritis disease gene of the present invention (hereinafter referred to as "RA disease gene") is a variant sequence of known protooncogene Dbl gene (EMBO J. 7(8): 2463-2473, 1988; GenBank Accession No. X12556) which is isolated from human chromosome X by the method described in the after-mentioned Examples. In other words, this Dbl gene transcribes the mRNA encoding the cDNA for which the sequence of the 2679th to 2952nd bases is represented in SEQ ID NO: 1, while in the cDNA of the variant gene, the sequence of the 3' side of the 241st base in SEQ ID NO: 1 is linked to the downstream side of the 18th base to induce a frame shift in amino acid translation, causing the 19th to 274th base in SEQ ID NO: 1 to be substituted by the sequence shown in SEQ ID NO: 2. Fig. 1 shows the base sequence of the 2679th to 2952nd bases (same as SEQ ID NO: 1) of Dbl gene cDNA in a normal, the corresponding base sequence of RA disease gene, and the respective amino acid sequences (1 letter notation) encoded by these sequences.

In addition, generally, polymorphism of individual differences is often found for human genes. Thus, the RA disease gene of the present invention may include genes that code cDNAs obtained by the addition, deletion or substitution of one or more nucleotide in SEQ ID NO: 2. Likewise, the present invention also includes proteins with one or more amino acid added to, deleted from and/or substituted, produced by such change to the base.

The cDNAs of the present invention may easily be isolated by, for example, the method described in the after-mentioned Example. Further, the cDNAs of the present invention may be cloned from a cDNA library produced by a known method (Mol. Cell. Biol. 2:161-170, 1982; J. Gene 25: 263-269, 1983; Gene 150: 243-250, 1994) using poly(A)+RNA extracted from cells of a patient with rheumatoid arthritis. Such cloning may be performed by, for example, synthesizing oligonucleotides based on the sequence information provided by the present invention and screening by colony or plaque hybridization by a known method using the resultant oligonucleotides as probes. Also, oligonucleotides, which hybridize to both ends of the target cDNA fragment, may be synthesized, and using them as primers, the cDNA of the present invention may be produced by RT-PCR method from mRNAs isolated from cells of a patient with rheumatoid arthritis.

The DNA fragment of the present invention comprises a

portion of the aforesaid cDNA, and contains the base sequence shown in SEQ ID NO: 3. In other words, SEQ ID NO: 3 is the underlined sequence in Figure 1, and is a characteristic region, which is not present in normal Dbl gene or its cDNAs. Further, the DNA fragment includes both sense and antisense strands. These DNA fragments may be used as probes for genetic diagnosis.

The proteins of the present invention are expression products resulting from the RA disease genes of the present invention, and has the amino acid sequence shown in SEQ ID NO: 2 at its C-terminal. These proteins may be obtained by chemical peptide synthesis method based on the amino acid sequence provided by the present application, or by recombinant DNA technique using cDNAs provided by the present application. For example, when recombinant DNA technique is used to obtain the proteins, RNA may be prepared by *in vitro* transcription using a vector containing the cDNA of the present invention; using this RNA as a template, the proteins may be obtained by *in vitro* translation. Also, the coding region of the cDNA may be recombined into an appropriate expression vector by any known method, and the recombinant vector obtained may be used to transform *E. coli.*, *Bacillus subtilis*, yeast, animal cells or the like, whereby expression of the protein in bulk would be possible using these recombinant cells.

When *in vitro* translation is used to produce the proteins of the present invention, the coding region of the cDNA of the

present invention may be recombined into a vector with RNA polymerase promoter, and introduced into the *in vitro* translation system containing the RNA polymerase corresponding to the promoter, such as rabbit reticular erythrocyte lysate or wheat embryo extracts. T7, T3 and SP6 may be listed as examples of the RNA polymerase promoter. Examples of vectors, which contain any of these RNA polymerase promoters are pKA1, pCDM8, pT3/T7 18, pT7/3 19 and pBluescript II.

Furthermore, when the proteins of the present invention are expressed using microorganisms such as *E. coli.*, a recombinant expression vector may be prepared by incorporating the coding region of the cDNA of the present invention into an expression vector which contains replication origin replicable in microorganism, promoter, ribosome-binding site, cDNA cloning site, terminator and the like, which is then used to transform a host cell and incubating the transformed cell. In such cases, by adding initiation and termination codons before and after an arbitrary coding region, protein fragments, which contain the arbitrary region may be obtained. Alternatively, the protein may be obtained as a fusion protein with another protein. By cleaving the fusion protein using an appropriate protease, the target protein may also be isolated. Examples of the expression vector for *E. coli.* are pUC system, pBluescript II, pET expression system and pGEX expression system.

When expressing the protein of the present invention in

eucaryotic cells, the coding region of the inventive cDNA may be incorporated into an expression vector for eucaryotic cells that contains a promoter, a splicing region, a poly(A) addition site and the like, which may be introduced into eucaryotic cells.

5 Such expression vectors may be pKA1, pCDM8, pSVK3, pMSG, pSVL, pBK-CMV, pBK-RSV, EBV vector, pRS and pYES2. Generally, mammal culture cells such as monkey kidney cell COS7 or Chinese hamster ovarian cell CHO, budding yeast, fission yeast, silkworm cells and *Xenopus laevis* o-site cells are used as eucaryotic cells,
10 but in the present invention, they are not limited to these examples. To introduce the expression vector into eucaryotic cells, any known method such as electroporation, calcium phosphate method, liposome method, and DEAE dextran method may be used.

15 After the proteins are expressed in procaryotic or eucaryotic cells by the above-described methods, the protein of interest may be separated from the culture and purified by using combinations of known separation/purification methods. Examples are, treatment with degenerating agents such as urea
20 or surfactant, ultrasonication, enzyme digestion, salt- or solvent-precipitation, dialysis, centrifugation, ultrafiltration, gel filtration, SDS-PAGE, isoelectric focusing method, ion-exchange chromatography, hydrophobic chromatography, affinity chromatography, reverse phase
25 chromatography and the like.

Further, the protein of the present invention also encompasses fusion proteins of the present protein with other arbitrary protein.

The peptide of the present invention is a peptide fragment,
5 which contains at least part (5 amino acid residues or more) of the amino acid sequence shown in SEQ ID NO: 2. Such peptide may be used as an antigen for preparing an antibody.

The antibody of the present invention may be obtained as a polyclonal or monoclonal antibody by any known method using
10 the protein itself or a partial peptide thereof as antigen.

The method for diagnosing rheumatoid arthritis of the present invention may be performed, for example, by detecting the presence of characteristic mRNAs transcribed by RA disease gene in a biological specimen (body fluid, cell) obtained from
15 a subject. Such mRNA may be detected by, for example, RT-PCR amplification of the mRNA containing the characteristic region (e.g., the underlined region in Figure 1), or by *in vitro* or *insitu* hybridization analysis using any characteristic sequence region of the mRNA for RA disease gene as a probe.

Furthermore, the method for diagnosing rheumatoid
20 arthritis of the present invention may also be performed by detecting the presence of protein(s) expressed from RA disease gene in a biological specimen of a subject. Such detection may be performed by, for example, enzyme immunoassay or
25 radioimmunoassay using the antibody of the present invention.

Further, the presence of such gene expression or protein may be detected by using any diagnosis kit; for example, hybridization analysis kit such as DNA chip and the like or immunoassay kit such as ELISA kit may be used.

5 The Dbl defect of the present invention may be complemented by, for example, protein or low molecular weight compounds.

Examples

10 Hereinafter, the RA disease gene of the present invention will be described in further detail through the following examples; however, the present invention is not limited to these examples.

<Example 1> Identification of the RA disease gene

15 For the gene analysis by affected sib-pair analysis method using microsatellite marker, DNAs were prepared from peripheral blood collected from a family of two rheumatoid arthritis patients and one normal, by the guanidine-thiocyanate method (The Japan Society of Blood Transfusion Report 40(2), 413).

20 Further, 11 markers (DXS1047, DXS8072, DXS8041, DXS8094, DXS1192, DXS1205, DXS1227, DXS8106, DX8043, DX8028 and DXS1200) (Nature 360, 1996) were selected as microsatellite markers with heterozygosity higher than about 0.7, from the range of the candidate genetic loci previously disclosed by the present

25 inventors (International Immunology 10(12): 1891-1895; Journal

of Clinical Rheumatology 4(3): 156-158, 1998), and fluorescence-labeled primers that could amplify each loci were synthesized at Perkin Elmer Inc. The sequences of the primer are disclosed in the above literature and are known. Each marker

5 region was isolated by PCR under the following conditions. The reaction solution was prepared by mixing 5pmol of primer, approximately 0.5µg of template DNA, 1.5µg of Buffer II (Perkin Elmer Inc.), 1.0µl of 2mM dNTP Mix (Perkin Elmer Inc.), 0.12µl of Ampli Taq Gold enzyme (Perkin Elmer Inc.) and 0.9µl of 25mM
10 MgCl₂ (Perkin Elmer Inc.), and adding sterilized water to obtain a total volume of 15µl. The reaction was performed in a thermal cycler (PTC-200) of MJ Research Inc. First, one cycle of enzyme activation at 95°C for 12 minute, 10 cycles of heat denaturation at 94°C for one minute, primer annealing at 47°C for one minute
15 and extension at 72°C for 2 minutes were performed, after which 20 cycles of heat denaturation at 89°C for one minute, primer annealing at 47°C for one minute and extension at 72°C for 2 minutes were performed. Each of the resultant DNA fragments were analyzed in a DNA sequencer (Perkin Elmer Inc., Type AB1377)
20 by subjecting to electrophoresis with size markers for Genescan (Perkin Elmer Inc.) of the manufacture's specification, and the DNA analysis was performed by using the attached softwares, Genescan and Genotyper. The data obtained were analyzed on Unix system using Mapmaker Sibs software (Am J Hum Genet, 57, 439-454,
25 1995), which is available to the public, for genetic linkage

analysis, and the maximum Lod value was calculated by single point analysis.

As a result, the maximum Lod was determined to be 2.03 for DXS984, which is located in the 0.1 centi Morgan vicinity of DXS1232, one of the candidate genetic loci disclosed by the present inventors (International Immunology 10(12): 1891-1895; Journal of Clinical Rheumatology 4(3): 156-158, 1998), showing significant correlation. By searching the international data base on the internet (Genemap98, <http://www.ncbi.nlm.nih.gov/genemap98/>), it was found that the physical location of DXS984 was 4259 cR10000(F) on the G3 Radiation hybrid map, and thus it was proved that the protooncogene Dbl was situated nearest to DXS984.

<Example 2> Analysis of Abnormal Dbl Gene

In order to compare the cDNAs between Dbl genes, cDNA was synthesized by reverse transcription using RT-PCR kit (Perkin Elmer Inc.) from the total RNA obtained from peripheral blood of RA disease patients collected using Isogen agent (Nippongene Co. Ltd.), and dissolved in 20 μ l of sterilized water. Furthermore, primers (SEQ ID NO: 4 and 5) were prepared using the Dbl cDNA sequence (Genbank Accession No. X12556) (Amersham Pharmacia), and part of the Dbl cDNA sequence was isolated by the PCR method. The composition of the reaction solution for PCR was: 10 pmol each of forward primer (SEQ ID NO: 4) and reverse primer (SEQ ID NO: 5), approximately 0.1 μ g of template DNA, 2.5 μ l

of LA-PCR buffer (Takara Shuzo Co. Ltd.), 4.0μl of 2.5mM dNTP Mix, 0.25μl of LA Taq enzyme (Takara Shuzo Co. Ltd.) and 2.5μl of 25mM MgCl₂ mixed, after which sterilized water was added to obtain a total volume of 25μl. The reaction was performed in a thermal cycler (PTC-200) of MJ Research by repeating 35 cycles of the process of heat denaturation at 94°C for 30 seconds, primer annealing at 52°C for 30 seconds and extension at 72°C for 2 minutes. The PCR products were subjected to electrophoresis of conventional methods, in TAE buffer solution using 1% Agarose L (Nippongene Co. Ltd.) gel and DNA molecular weight markers (200bp ladder) by Promega Co., to confirm the amplified bands. As a result, it was found that the size of normal DNA was 660bp while the size of DNA chain from some patients were distinctly shorter (approximately 440bp).

Next, after each respective bands were cut out, the gels were melted at 65°C for 10 minutes, and the DNAs were purified by conventional phenol extraction methods and ethanol precipitation methods. Then, using 100ng of the resultant DNA as a template, cycle sequence reaction and purification were performed following the specifications of the manufacturer of BigDye terminator cycle sequence kit by Perkin Elmer Inc., and the sequence was determined by a Type AB1377 DNA sequencer of Perkin Elmer Inc. As a result, it was evident that in the above-described abnormally short DNA, as shown in Fig. 1, the 223bp from the number 2697 to number 2919 bases are deleted,

making it 437 bp. This result indicates that with the amino acid deletion encoded in the genetic information downstream of base number 2693, and by inducing frame shift, abnormal polypeptide chain short of 65 amino acids is produced.

5

Industrial Applicability

As described in detail above, the present invention provides a disease gene for rheumatoid arthritis occurring in human chromosome X. This invention enables the easy and reliable diagnosis of rheumatoid arthritis. Furthermore, this invention is useful for the development of novel treatment and therapeutic agents for rheumatoid arthritis.

10

CLAIMS

1. A disease gene for rheumatoid arthritis, which is a mutant of protooncogene Dbl transcribing an mRNA that encodes the cDNA of which the sequence from the 2679th to 2952nd bases is shown in SEQ ID NO: 1, which disease gene transcribes an mRNA encoding the cDNA of which the region from the 20th to 274th bases in SEQ ID NO: 1 is substituted with the sequence of SEQ ID NO: 2.

2. The cDNA of the disease gene of claim 1.

3. A DNA fragment, which is a part of the disease gene of claim 1 or the cDNA of claim 2, and contains the base sequence of SEQ ID NO: 3.

4. A protein which is an expression product of the disease gene of claim 1, wherein the amino acid sequence of the C-terminal is that shown in SEQ ID NO: 2.

5. A peptide, which is a part of the protein of claim 4, and contains partial sequence of the amino acid sequence shown in SEQ ID NO: 2.

6. An antibody against the protein of claim 4 or the peptide of claim 5.

7. A method for diagnosing rheumatoid arthritis, comprising the detection of the mRNA from the disease gene of claim 1 or the protein of claim 4, in a biological specimen.

8. A method for functionally complementing Dbl deficiency.

DECLARATION AND POWER OF ATTORNEY FOR U.S. PATENT APPLICATION

(X) Original () Supplemental () Substitute (X) PCT () DESIGN

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that I verily believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Title: RHEUMATOID ARTHRITIS GENE AND METHOD FOR DIAGNOSING RHEUMATOID ARTHRITIS

of which is described and claimed in:

() the attached specification, or

(X) the specification in application Serial No. NEW, filed September 19, 2001, and with amendments through _____, or

(X) the specification in International Application No. PCT/JP00/01697, filed March 21, 2000, and as amended on _____ (if applicable).

I hereby state that I have reviewed and understand the content of the above-identified specification, including the claims, as amended by any amendment(s) referred to above.

I acknowledge my duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim priority benefits under Title 35, United States Code, §119 (and §172 if this application is for a Design) of any application(s) for patent or inventor's certificate listed below and have also identified below any application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

COUNTRY	APPLICATION NO.	DATE OF FILING	PRIORITY CLAIMED
Japan	1999-116933	March 20, 1999	Yes

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	U.S. FILING DATE	STATUS: PATENTED, PENDING, ABANDONED

And I hereby appoint Michael R. Davis, Reg. No. 25,134; Matthew M. Jacob, Reg. No. 25,154; Warren M. Check, Jr., Reg. No. 33,367; Nils Pedersen, Reg. No. 33,145; Charles R. Watts, Reg. No. 33,142; and Michael S. Huppert, Reg. No. 40,268, who together constitute the firm of WENDEROTH, LIND & PONACK, L.L.P., as well as any other attorneys and agents associated with Customer No. 000513, to prosecute this application and to transact all business in the U.S. Patent and Trademark Office connected therewith.

I hereby authorize the U.S. attorneys and agents named herein to accept and follow instructions from NISHIZAWA & ASSOCIATES as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. attorneys and myself. In the event of a change in the persons from whom instructions may be taken, the U.S. attorneys named herein will be so notified by me.

Direct Correspondence to Customer No:



000513

PATENT TRADEMARK OFFICE

Direct Telephone Calls to:

WENDEROTH, LIND & PONACK, L.L.P.
2033 "K" Street, N.W., Suite 800
Washington, D.C. 20006-1021

Phone: (202) 721-8200
Fax: (202) 721-8250

Full Name of First Inventor	FAMILY NAME SHIOZAWA	FIRST GIVEN NAME Shunichi	SECOND GIVEN NAME
Residence & Citizenship	CITY Hyogo	STATE OR COUNTRY Japan	COUNTRY OF CITIZENSHIP Japan
Post Office Address	ADDRESS 11-6, Takeno-dai 2-chome,	CITY Nishi-ku,	STATE OR COUNTRY Kobe-shi, Hyogo, Japan
Full Name of Second Inventor	FAMILY NAME KOMAI	FIRST GIVEN NAME Koichiro	SECOND GIVEN NAME
Residence & Citizenship	CITY Hyogo	STATE OR COUNTRY Japan	COUNTRY OF CITIZENSHIP Japan
Post Office Address	ADDRESS 12-8, Soen 1-chome,	CITY Hanayashiki,	STATE OR COUNTRY Takarazuka-shi, Hyogo, Japan
Full Name of Third Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP
Post Office Address	ADDRESS	CITY	STATE OR COUNTRY ZIP CODE
Full Name of Fourth Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP
Post Office Address	ADDRESS	CITY	STATE OR COUNTRY ZIP CODE
Full Name of Fifth Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP
Post Office Address	ADDRESS	CITY	STATE OR COUNTRY ZIP CODE
Full Name of Sixth Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP
Post Office Address	ADDRESS	CITY	STATE OR COUNTRY ZIP CODE

I further declare that all statements made herein of my own knowledge are true, and that all statements on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

1st Inventor *Shunichi Shiozawa* Date October 17, 2001
Shunichi SHIOZAWA
2nd Inventor *Koichiro Komai* Date October 17, 2001
Koichiro KOMAI
3rd Inventor _____ Date _____
4th Inventor _____ Date _____
5th Inventor _____ Date _____
6th Inventor _____ Date _____

The above application may be more particularly identified as follows:

U.S. Application Serial No. NEW Filing Date September 19, 2001

Applicant Reference Number 00-F-007PCT-US/SH Atty Docket No. 2001 1298A

Title of Invention RHEUMATOID ARTHRITIS GENE AND METHOD FOR DIAGNOSING RHEUMATOID ARTHRITIS

SEQUENCE LISTING

<110> Shunichi SHIOZAWA

<120> RHEUMATOID ARTHRITIS GENE AND METHOD FOR DIAGNOSING RHEUMATOID ARTHRITIS

<130> 2001/1298A/WMC/00653

<140> NEW

<141> 2001-09-19

<150> JP11-116933

<151> 1999-03-20

<160> 5

<170> PatentIn Ver.2.0

<210> 1

<211> 274

<212> DNA

<213> Homo sapiens

<221> CDS

<222> (2)..(271)

<308> GenBank Accession No.X12556

<400> 1

```
t ctt cag cag aat gat gaa aag caa cag gga gct ttt ata agt act gag 49
  Leu Gln Gln Asn Asp Glu Lys Gln Gln Gly Ala Phe Ile Ser Thr Glu
    1           5           10           15
gaa act gaa ttg gaa cac acc agc act gtg gtg gag gtc tgt gag gca 97
Glu Thr Glu Leu Glu His Thr Ser Thr Val Val Glu Val Cys Glu Ala
    20           25           30
att gcg tca gtt cag gca gaa gca aat aca gtt tgg act gag gca tca 145
Ile Ala Ser Val Gln Ala Glu Ala Asn Thr Val Trp Thr Glu Ala Ser
    35           40           45
caa tct gta gaa atc tct gaa gaa cct gcg gaa tgg tca agc aac tat 193
Gln Ser Val Glu Ile Ser Glu Glu Pro Ala Glu Trp Ser Ser Asn Tyr
    50           55           60
ttc tac ccc act tat gat gaa aat gaa gaa gaa aat agg ccc ctc atg 241
Phe Tyr Pro Thr Tyr Asp Glu Asn Glu Glu Glu Asn Arg Pro Leu Met
    65           70           75           80
aga cct gtg tcg gag atg gct ctc cta tat tga 274
Arg Pro Val Ser Glu Met Ala Leu Leu Tyr
    85           90
```

<210> 2

<211> 61

<212> DNA

<213> Homo sapiens

<221> CDS

<222> (1)..(60)

<400> 2

a gac ctg tgt cgg aga tgg ctc tcc tat att gat gaa gct act atg tca 49
Asp Leu Cys Arg Arg Trp Leu Ser Tyr Ile Asp Glu Ala Thr Met Ser
1 5 10 15
aat ggc aag tag 61
Asn Gly Lys
19

<210> 3

<211> 10

<212> DNA

<213> Homo sapiens

<400> 3

atgaagacct 10

<210> 4

<211> 19

<212> DNA

<213> Artificial sequence

<220>

<223> Synthesized oligonucleotide

<400> 4

ggctagattc aaaccaatg 19

<210> 5

<211> 17

<212> DNA

<213> Artificial sequence

<220>

<223> Synthesized oligonucleotide

<400> 5

gctacttgcc atttgac 17